Stem cell's shell game?
By Capitol Weekly,
Capitol Weekly
| 09. 22. 2005
The biggest question surrounding stem cell research in California right now isn_t whether it will eventually cure devastating health problems. It_s what happened to the billion dollars.
When California voters approved Proposition 71 last year, critics say, it was partially on the promise that their $3 billion investment in stem cell research would provide a financial payoff to the state. Supporters cited a study that claimed California could get a payback of anywhere between $537 million and $1.1 billion from royalties and licensing from intellectual property, or IP, as it is known in the investment community.
Actually, the figures were never written into the law that voters approved--the latest surprise disclosure surrounding the controversial initiative. And the study itself was financed by the backers of Proposition 71.
That means perhaps $1 billion or more that many expected Proposition 71 to provide to California may not be coming, after all. The numbers came from a September 2004 analysis produced by Dr. Laurence Baker, an associate professor of the Stanford University School of Medicine, and Bruce Deal, managing partner of the Analysis...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...